New developments in the neurobiological basis of anxiety disorders.

Jack M. Gorman, Robert M A Hirschfeld, Philip T. Ninan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Generalized anxiety disorder (GAD) is a chronic disorder that often precedes the development of, and is comorbid with, depression. Investigation of the neurobiological basis of GAD has provided suggestive evidence to implicate dysfunction of serotonergic and noradrenergic systems in the expression of GAD, as well as the depressive disorders. Hence, there may be a neurobiological link between GAD and depression through the activity of the serotonin and norepinephrine systems. The use of various anxiolytics and antidepressants, including benzodiazepines, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors in the treatment of GAD is reviewed. The neurobiological relationship between GAD and depression, and the frequent comorbidity of these disorders, suggests that agents with a dual action on the serotonin and norepinephrine systems may potentially offer superior benefits in the management of patients with anxiety and depressive disorders.

Original languageEnglish (US)
Pages (from-to)49-67
Number of pages19
JournalPsychopharmacology Bulletin
Volume36 Suppl 2
StatePublished - Jun 2002

Fingerprint

Anxiety Disorders
Depression
Depressive Disorder
Serotonin
Norepinephrine
Tricyclic Antidepressive Agents
Anti-Anxiety Agents
Serotonin Uptake Inhibitors
Benzodiazepines
Antidepressive Agents
Comorbidity

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Gorman, J. M., Hirschfeld, R. M. A., & Ninan, P. T. (2002). New developments in the neurobiological basis of anxiety disorders. Psychopharmacology Bulletin, 36 Suppl 2, 49-67.

New developments in the neurobiological basis of anxiety disorders. / Gorman, Jack M.; Hirschfeld, Robert M A; Ninan, Philip T.

In: Psychopharmacology Bulletin, Vol. 36 Suppl 2, 06.2002, p. 49-67.

Research output: Contribution to journalArticle

Gorman, JM, Hirschfeld, RMA & Ninan, PT 2002, 'New developments in the neurobiological basis of anxiety disorders.', Psychopharmacology Bulletin, vol. 36 Suppl 2, pp. 49-67.
Gorman JM, Hirschfeld RMA, Ninan PT. New developments in the neurobiological basis of anxiety disorders. Psychopharmacology Bulletin. 2002 Jun;36 Suppl 2:49-67.
Gorman, Jack M. ; Hirschfeld, Robert M A ; Ninan, Philip T. / New developments in the neurobiological basis of anxiety disorders. In: Psychopharmacology Bulletin. 2002 ; Vol. 36 Suppl 2. pp. 49-67.
@article{9e4e0ca65af94b5fa6b2ffea9b3eb3b5,
title = "New developments in the neurobiological basis of anxiety disorders.",
abstract = "Generalized anxiety disorder (GAD) is a chronic disorder that often precedes the development of, and is comorbid with, depression. Investigation of the neurobiological basis of GAD has provided suggestive evidence to implicate dysfunction of serotonergic and noradrenergic systems in the expression of GAD, as well as the depressive disorders. Hence, there may be a neurobiological link between GAD and depression through the activity of the serotonin and norepinephrine systems. The use of various anxiolytics and antidepressants, including benzodiazepines, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors in the treatment of GAD is reviewed. The neurobiological relationship between GAD and depression, and the frequent comorbidity of these disorders, suggests that agents with a dual action on the serotonin and norepinephrine systems may potentially offer superior benefits in the management of patients with anxiety and depressive disorders.",
author = "Gorman, {Jack M.} and Hirschfeld, {Robert M A} and Ninan, {Philip T.}",
year = "2002",
month = "6",
language = "English (US)",
volume = "36 Suppl 2",
pages = "49--67",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",

}

TY - JOUR

T1 - New developments in the neurobiological basis of anxiety disorders.

AU - Gorman, Jack M.

AU - Hirschfeld, Robert M A

AU - Ninan, Philip T.

PY - 2002/6

Y1 - 2002/6

N2 - Generalized anxiety disorder (GAD) is a chronic disorder that often precedes the development of, and is comorbid with, depression. Investigation of the neurobiological basis of GAD has provided suggestive evidence to implicate dysfunction of serotonergic and noradrenergic systems in the expression of GAD, as well as the depressive disorders. Hence, there may be a neurobiological link between GAD and depression through the activity of the serotonin and norepinephrine systems. The use of various anxiolytics and antidepressants, including benzodiazepines, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors in the treatment of GAD is reviewed. The neurobiological relationship between GAD and depression, and the frequent comorbidity of these disorders, suggests that agents with a dual action on the serotonin and norepinephrine systems may potentially offer superior benefits in the management of patients with anxiety and depressive disorders.

AB - Generalized anxiety disorder (GAD) is a chronic disorder that often precedes the development of, and is comorbid with, depression. Investigation of the neurobiological basis of GAD has provided suggestive evidence to implicate dysfunction of serotonergic and noradrenergic systems in the expression of GAD, as well as the depressive disorders. Hence, there may be a neurobiological link between GAD and depression through the activity of the serotonin and norepinephrine systems. The use of various anxiolytics and antidepressants, including benzodiazepines, tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors in the treatment of GAD is reviewed. The neurobiological relationship between GAD and depression, and the frequent comorbidity of these disorders, suggests that agents with a dual action on the serotonin and norepinephrine systems may potentially offer superior benefits in the management of patients with anxiety and depressive disorders.

UR - http://www.scopus.com/inward/record.url?scp=34547471110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547471110&partnerID=8YFLogxK

M3 - Article

C2 - 12490823

AN - SCOPUS:34547471110

VL - 36 Suppl 2

SP - 49

EP - 67

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

ER -